Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump
Status:
Completed
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this investigator-initiated trial is to compare the effect of a daily
injection of insulin degludec vs. basal insulin delivery via Continuous Subcutaneous Insulin
Infusion (CSII), both in combination with bolus insulin delivery via the patient's usual
insulin pump with insulin aspart, on glycemic variability, overall blood glucose control and
incidence of hypoglycemia, all assessed by continuous glucose monitor (CGM), as well as
patient satisfaction, in patients with type 1 diabetes currently using CSII.